Actionable news
All posts from Actionable news
Actionable news in GILD: Gilead Sciences, Inc.,

Could a Spin-off of its Hepatitis C Division be in Gilead's Future?

Gilead (GILD) could be both a buyer and a seller in coming months, as analysts and investors speculate about the company's need for assets that could boost revenue as well as its floundering hepatitis division.

One idea that has been floated in financial circles is a spin-off of the company's hepatitis C division, which saw an 18% year-over-year decline in sales for the second quarter of 2016. This primarily came from Gilead's three hepatitis C drugs, Harvoni, Sovaldi and Epclusa.

JUST UPDATED – TheStreet's Biotech Bible! Before you invest one single dime...